+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Pembrolizumab"

From
From
From
From
From
Head and Neck Cancer Therapeutics: Global Markets - Product Thumbnail Image

Head and Neck Cancer Therapeutics: Global Markets

  • Report
  • August 2022
  • 148 Pages
  • Global
From
Immunotherapy Drugs: Global Markets - Product Thumbnail Image

Immunotherapy Drugs: Global Markets

  • Report
  • March 2021
  • 143 Pages
  • Global
From
Checkpoint Inhibitors: Global Markets - Product Thumbnail Image

Checkpoint Inhibitors: Global Markets

  • Report
  • October 2018
  • 141 Pages
  • Global
From
From
From
From
From
From
Checkpoint Inhibitors - Competitive landscape, 2023 - Product Thumbnail Image

Checkpoint Inhibitors - Competitive landscape, 2023

  • Report
  • April 2023
  • 350 Pages
  • Global
From
From
Lenvatinib + pembrolizumab Emerging Drug Insight and Market Forecast - 2032 - Product Thumbnail Image

Lenvatinib + pembrolizumab Emerging Drug Insight and Market Forecast - 2032

  • Drug Pipelines
  • December 2022
  • 30 Pages
  • Global
From
Oncolytic Virus - Competitive Landscape, 2022 - Product Thumbnail Image

Oncolytic Virus - Competitive Landscape, 2022

  • Report
  • October 2022
  • 300 Pages
  • Global
From
From
From
From
Loading Indicator

Pembrolizumab is a type of oncology drug used to treat certain types of cancer. It is a monoclonal antibody, which works by targeting and blocking a protein called PD-1, which is found on the surface of some cancer cells. This helps the body's immune system to recognize and attack the cancer cells. Pembrolizumab is used to treat a variety of cancers, including melanoma, non-small cell lung cancer, head and neck cancer, Hodgkin lymphoma, and urothelial carcinoma. It is also used in combination with other drugs to treat certain types of advanced or metastatic cancers. Pembrolizumab is approved by the US Food and Drug Administration (FDA) and is available in the US and other countries. It is typically administered intravenously, and the dosage and duration of treatment depend on the type and stage of cancer being treated. Some companies in the Pembrolizumab market include Merck & Co., Inc., Bristol-Myers Squibb, AstraZeneca, and Roche. Show Less Read more